Should I buy or sell Eiger BioPharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EIGR shares. View EIGR analyst ratings or view top-rated stocks .

What is Eiger BioPharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 1-year target prices for Eiger BioPharmaceuticals' shares. Their EIGR share price targets range from $3.00 to $9.00. On average, they anticipate the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 1,615.1% from the stock's current price. View analysts price targets for EIGR or view top-rated stocks among Wall Street analysts .

How have EIGR shares performed in 2023?

Eiger BioPharmaceuticals' stock was trading at $1.18 at the beginning of the year. Since then, EIGR stock has decreased by 72.0% and is now trading at $0.3304. View the best growth stocks for 2023 here .

Are investors shorting Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,010,000 shares, a decrease of 5.6% from the October 31st total of 1,070,000 shares. Based on an average trading volume of 324,600 shares, the days-to-cover ratio is presently 3.1 days. View Eiger BioPharmaceuticals' Short Interest .

When is Eiger BioPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our EIGR earnings forecast .

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.07. The biotechnology company had revenue of $3.04 million for the quarter, compared to analysts' expectations of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%. During the same period last year, the firm posted ($0.52) earnings per share.

What ETF holds Eiger BioPharmaceuticals' stock ?

Simplify Propel Opportunities ETF holds 1,099,653 shares of EIGR stock, representing 0.75% of its portfolio.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN) , Gilead Sciences (GILD) , Skyworks Solutions (SWKS) , ZIOPHARM Oncology (ZIOP) , Amarin (AMRN) , Celldex Therapeutics (CLDX) , Catalyst Pharmaceuticals (CPRX) , Exelixis (EXEL) , SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO) .

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (5.98%), GSA Capital Partners LLP (0.80%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Apelian, Eldon C Mayer III , Evan Loh , Richard A Kayne, Sriram Ryali and Thomas John Dietz . View institutional ownership trends .

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Eiger BioPharmaceuticals Stock Price, News & Analysis (NASDAQ:EIGR)

$0.33

+0.00 (+0.06%)

(As of 01:18 PM ET)

Compare

Today's Range: $0.32
▼
$0.34
50-Day Range: $0.22
▼
$0.43
52-Week Range: $0.21
▼
$4.62

Volume: 42,258 shs
Average Volume: 457,652 shs
Market Capitalization: $14.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.67

Eiger BioPharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,615.1% Upside
$5.67 Price Target
Short Interest: Healthy
2.28% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.65
Upright™ Environmental Score
News Sentiment: 0.96
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$44,181 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.64) to ($0.52) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

41st out of 949 stocks

Biological Products, Except Diagnostic Industry

5th out of 162 stocks

3.5

Analyst's Opinion

Consensus Rating
Eiger BioPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.67, Eiger BioPharmaceuticals has a forecasted upside of 1,615.1% from its current price of $0.33.
Amount of Analyst Coverage
Eiger BioPharmaceuticals has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.28% of the outstanding shares of Eiger BioPharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Eiger BioPharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eiger BioPharmaceuticals has recently decreased by 5.61%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Eiger BioPharmaceuticals does not currently pay a dividend.
Dividend Growth
Eiger BioPharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Eiger BioPharmaceuticals has received a 61.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Lonafarnib" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Eiger BioPharmaceuticals is -1.65.

3.3

News and Social Media Coverage

News Sentiment
Eiger BioPharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Eiger BioPharmaceuticals this week, compared to 1 article on an average week.
Search Interest
3 people have searched for EIGR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Eiger BioPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eiger BioPharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,181.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.54% of the stock of Eiger BioPharmaceuticals is held by insiders.
Percentage Held by Institutions
62.46% of the stock of Eiger BioPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Eiger BioPharmaceuticals are expected to grow in the coming year, from ($1.64) to ($0.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eiger BioPharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eiger BioPharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

EIGR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EIGR Stock News Headlines

November 24, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

November 11, 2023 | finanznachrichten.de

Eiger BioPharmaceuticals, Inc.: Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

September 15, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Ocular Therapeutix (OCUL), Eiger Biopharmaceuticals (EIGR)

September 13, 2023 | marketwatch.com

Eiger BioPharmaceuticals Shares Hit New Lows After Scrapped Hepatitis D Study

September 13, 2023 | markets.businessinsider.com

Eiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In Premarket

September 13, 2023 | msn.com

Why Is Hepatitis Player Eiger BioPharma Stock Trading Lower Today?

September 13, 2023 | investorplace.com

Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

September 13, 2023 | reuters.com

Eiger to discontinue late-stage hepatitis drug study over safety concerns

September 12, 2023 | news.yahoo.com

Eiger to discontinue hepatitis drug study over safety concerns

September 12, 2023 | marketwatch.com

Eiger BioPharmaceuticals to Discontinue Chronic Hepatitis Delta Study, Ends Licensing Talks

September 12, 2023 | seekingalpha.com

Eiger to stop late stage trial in hepatitis D patients, stock slumps ~36% after hours

September 12, 2023 | finance.yahoo.com

UPDATE 1-Eiger to discontinue hepatitis drug study over safety concerns

September 12, 2023 | reuters.com

Eiger to discontinue hepatitis drug study

August 30, 2023 | markets.businessinsider.com

Citi Sticks to Their Buy Rating for Eiger Biopharmaceuticals (EIGR)

August 15, 2023 | finanznachrichten.de

Eiger BioPharmaceuticals, Inc.: Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Eiger Biopharmaceuticals (EIGR) and Atossa Therapeutics (ATOS)

August 14, 2023 | markets.businessinsider.com

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 3, 2023 | yahoo.com

Freewell Eiger matte box aims to transform your filmmaking

July 6, 2023 | msn.com

Eiger BioPharmaceuticals (EIGR) Price Target Decreased by 59.60% to 3.40

July 1, 2023 | msn.com

Baird Maintains Eiger BioPharmaceuticals (EIGR) Outperform Recommendation

June 30, 2023 | markets.businessinsider.com

Potential Upside For Eiger's Avexitide In Both PBH And CHI Indications: Analyst

June 29, 2023 | msn.com

Eiger cuts 25% of staff in portfolio reorganization

June 29, 2023 | msn.com

Eiger BioPharmaceuticals Makes Interim CEO Permanent, It Chalks Out Portfolio Prioritization Review, Layoffs

June 29, 2023 | markets.businessinsider.com

Eiger Biopharmaceuticals (EIGR) Gets a Buy from Ladenburg Thalmann & Co.

June 28, 2023 | finance.yahoo.com

Eiger BioPharmaceuticals to Host Business Update Call Tomorrow

See More Headlines

Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EIGR
CUSIP: N/A
CIK: 1305253
Web: www.eigerbio.com
Phone: (650) 272-6138
Fax: 650-618-1621
Employees: 56
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.67
High Stock Price Target: $9.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +1,615.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-96,780,000.00
Net Margins: -590.80%
Pretax Margin: -590.79%
Return on Equity: -332.49%
Return on Assets: -99.77%

Debt

Debt-to-Equity Ratio: 2.64
Current Ratio: 3.31
Quick Ratio: 3.24

Sales & Book Value

Annual Sales: $13.48 million
Price / Sales: 1.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.04) per share
Price / Book: -8.26

Miscellaneous

Outstanding Shares: 44,380,000
Free Float: 42,814,000
Market Cap: $14.66 million
Optionable: Not Optionable
Beta: 1.89

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. David Apelian M.B.A. (Age 58)
M.D., Ph.D., CEO & Director
Comp: $204.39k
Dr. Jeffrey S. Glenn M.D. (Age 60)
Ph.D., Scientific Founder & Independent Director
Comp: $67k
Mr. Eldon C. Mayer III (Age 62)
M.B.A., Chief Commercial Officer
Comp: $586.96k
Mr. William G. Kaichoff CPA (Age 57)
CFO and Principal Financial & Accounting Officer
Mr. Christopher A. Kurtz (Age 56)
Chief Technical Officer
Mr. James Vollins J.D. (Age 54)
General Counsel, Chief Compliance Officer & Corporate Secretary
Dr. Ingrid C. Choong
Senior Vice President of Clinical Development
Dr. Colin Hislop M.D. (Age 65)
MBBS, Senior Vice President of Clinical & Development Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EIGR Stock Analysis - Frequently Asked Questions

Should I buy or sell Eiger BioPharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings or view top-rated stocks.
What is Eiger BioPharmaceuticals' stock price target for 2024?: 2 Wall Street research analysts have issued 1-year target prices for Eiger BioPharmaceuticals' shares. Their EIGR share price targets range from $3.00 to $9.00. On average, they anticipate the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 1,615.1% from the stock's current price.
View analysts price targets for EIGR or view top-rated stocks among Wall Street analysts.
How have EIGR shares performed in 2023?: Eiger BioPharmaceuticals' stock was trading at $1.18 at the beginning of the year. Since then, EIGR stock has decreased by 72.0% and is now trading at $0.3304.
View the best growth stocks for 2023 here.
Are investors shorting Eiger BioPharmaceuticals?: Eiger BioPharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,010,000 shares, a decrease of 5.6% from the October 31st total of 1,070,000 shares. Based on an average trading volume of 324,600 shares, the days-to-cover ratio is presently 3.1 days.
View Eiger BioPharmaceuticals' Short Interest.
When is Eiger BioPharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our EIGR earnings forecast.
How were Eiger BioPharmaceuticals' earnings last quarter?: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.07. The biotechnology company had revenue of $3.04 million for the quarter, compared to analysts' expectations of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%. During the same period last year, the firm posted ($0.52) earnings per share.

What ETF holds Eiger BioPharmaceuticals' stock ?: Simplify Propel Opportunities ETF holds 1,099,653 shares of EIGR stock, representing 0.75% of its portfolio.
What other stocks do shareholders of Eiger BioPharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).
Who are Eiger BioPharmaceuticals' major shareholders?: Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (5.98%), GSA Capital Partners LLP (0.80%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Richard A Kayne, Sriram Ryali and Thomas John Dietz.
View institutional ownership trends.
How do I buy shares of Eiger BioPharmaceuticals?: Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EIGR) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial